- Report
- January 2022
- 60 Pages
Global
From €1922EUR$2,000USD£1,650GBP
- Report
- January 2022
- 60 Pages
Global
From €1441EUR$1,500USD£1,237GBP
- Report
- January 2022
- 60 Pages
Global
From €1922EUR$2,000USD£1,650GBP
- Report
- January 2022
- 60 Pages
Global
From €1441EUR$1,500USD£1,237GBP
- Report
- August 2022
- 120 Pages
Global
From €4324EUR$4,500USD£3,712GBP
- Report
- November 2021
- 102 Pages
Global
From €4324EUR$4,500USD£3,712GBP
- Report
- December 2019
- 120 Pages
Global
From €3555EUR$3,700USD£3,052GBP
- Report
- November 2018
- 110 Pages
Global
From €4276EUR$4,450USD£3,671GBP
- Newsletter
- May 2024
- 4 Pages
Global
From €192EUR$200USD£165GBP
- Report
- May 2019
- 67 Pages
Global
€2878EUR$2,995USD£2,470GBP
- Report
- January 2018
- 19 Pages
Global
From €4804EUR$5,000USD£4,124GBP
- Report
- January 2018
- 137 Pages
Europe
From €7206EUR$7,500USD£6,186GBP
- Report
- November 2022
- 120 Pages
Global
From €2402EUR$2,500USD£2,062GBP
- Report
- July 2021
- 120 Pages
Global
From €2402EUR$2,500USD£2,062GBP
- Report
- March 2021
- 45 Pages
Global
From €2397EUR$2,495USD£2,058GBP
- Report
- February 2020
- 137 Pages
Global
From €7682EUR$7,995USD£6,595GBP
- Report
- December 2018
- 74 Pages
Global
From €4799EUR$4,995USD£4,120GBP
- Report
- August 2018
- 154 Pages
Global
From €7682EUR$7,995USD£6,595GBP
- Report
- August 2022
- 98 Pages
Middle East, Africa
From €1441EUR$1,500USD£1,237GBP
- Report
- August 2022
- 99 Pages
Asia Pacific
From €1441EUR$1,500USD£1,237GBP
The Biosimilars and Biosuperiors market is a rapidly growing sector of the pharmaceutical industry. Biosimilars are biologic drugs that are highly similar to an existing biologic drug, while biosuperiors are biologic drugs that are more effective than an existing biologic drug. Biosimilars and biosuperiors are used to treat a variety of conditions, including cancer, autoimmune diseases, and inflammatory diseases.
Biosimilars and biosuperiors are developed using advanced biotechnology techniques, such as recombinant DNA technology and monoclonal antibody technology. These drugs are designed to be more cost-effective than their original counterparts, while still providing the same therapeutic benefits.
The Biosimilars and Biosuperiors market is expected to continue to grow in the coming years, as more biologic drugs are developed and approved for use. Companies in this market include Amgen, Pfizer, Merck, and Novartis. Show Less Read more